You are here: Industry Insights > ESCC

News List

CStone announced two key phase 3 registrational clinical trials of sugemalimab completed patient enrollment prnasia
January 18, 2022
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines...
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Therapy for Esophageal Squamous Cell Carcinoma (ESCC) prnasia
September 28, 2021
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune...
Sintilimab in Combination with Chemotherapy Meets Overall Survival Primary Endpoint in the Global Phase 3 ORIENT-15 Study for the First-Line Treatment of Esophageal Squamous Cell Carcinoma prnasia
June 23, 2021
Innovent Biologics, Inc. today announced that the Phase 3 ORIENT-15 study met the predefined overall survival primary endpoint.
Tislelizumab reduces risk of death by 30 percent in oesophageal cancer trial europeanpharmaceuticalreview
June 08, 2021
In a Phase III trial, Novartis’ investigational checkpoint inhibitor tislelizumab improved overall survival in patients with oesophageal squamous cell carcinoma.
Novartis Tislelizumab Meets Primary Endpoint of Overall Survival in Esophageal Cancer americanpharmaceuticalreview
June 08, 2021
Novartis announced results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy (median 8.6 months vs. 6.3 months, p=0.0001).
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021 prnasia
June 07, 2021
Alphamab Oncology announced data from Phase 2 clinical study (KN046-204) of KN046(PD-L1/CTLA-4 bispecific antibody) plus paclitaxel/cisplatin for the first-line treatment of unresectable locally advanced, recurrent or metastatic esophageal squamous ...
CANbridge submits investigational new drug application for cancer treatment biospectrumasia
December 28, 2017
CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) In China